Tuesday, March 11, 2025
3/11/2025
Abstract Dr. Kim is an active and vital leader in the clinical trials program at The University of Michigan Rogel Cancer Center whose extensive, collaborative work has supported the NCI clinical trials infrastructure institutionally and nationally. Her key contributions to the mission and conduct of NCI-sponsored clinical trials include: 1) Institutional leadership of the Cancer Center Neuro-Oncology clinical research group and institutional Protocol Review Committee; 2) Serving as site Principal Investigator and central study team member for NCI-funded clinical trials; 3) National leadership as Co-Chair of the NIH/NCI Brain Metastases Interest Group and active member of NRG and Alliance Brain Tumor Committees; 4) National leadership in implementing practice- changing findings from NCI-funded clinical trials as member of the NCCN Guidelines CNS Cancers Committee and Senior Associate Editor of her specialty’s primary journal. Dr. Kim is an active investigator who has contributed 165 patient enrollments to interventional treatment and non-treatment (supportive and observational) trials since 2015, and has served as Principal Investigator of 5 investigator-initiated studies which she has developed and conducted. A recently completed trial is now in development as a multi-site study through the NRG Brain Tumor Committee. She has helped lead institutional and national efforts to broaden trial eligibility for underrepresented demographic and disease populations. Through the support of the Research Specialist Award, Dr. Kim proposes to advance the institutional clinical research mission, and to establish her research and national leadership contribution to NCI funded clinical trials. To address the Cancer Center’s objectives to increase accrual to interventional trials overall, and to increase institutional accrual of minorities and women, Dr. Kim proposes to launch a screening program across the entire Cancer Center to identify and enroll trial-eligible patients for CNS metastases-related trials (NCI-funded trials which have had suboptimal accrual). To expand the catchment of a more diverse patient population from the broader oncology community, she proposes to partner with University of Michigan affiliated community sites to develop streamlined processes for multi-site collaboration, launch a University of Michigan Network virtual tumor board to discuss cases and trial options, distribute newsletters and conduct CME events to increase awareness and participation in NCI-funded and investigator-initiated trials. She will finalize and conduct as Principal Investigator the initial phase of a developing Phase II/III Trial through NRG Oncology investigating an imaging biomarker to personalize radiotherapy in patients with glioblastoma. She will facilitate new inter-institutional collaborations and launch research initiatives as Co-Chair of the NIH/NCI Brain Metastases Interest Group, and will further advance in her participation and national leadership in support of NCI-funded clinical research.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).